Actuate Therapeutics (NASDAQ:ACTU) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Actuate Therapeutics (NASDAQ:ACTU) from a sell rating to a hold rating in a research report released on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Actuate Therapeutics in a research note on Friday, March 27th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $20.33.

Actuate Therapeutics Stock Performance

NASDAQ:ACTU opened at $2.10 on Friday. The firm has a market capitalization of $49.79 million, a price-to-earnings ratio of -2.00 and a beta of 0.85. Actuate Therapeutics has a 52-week low of $2.05 and a 52-week high of $11.99. The stock has a fifty day moving average of $3.47 and a 200 day moving average of $5.53.

Actuate Therapeutics (NASDAQ:ACTU) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.06.

Institutional Investors Weigh In On Actuate Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. BIOS Capital Management LP lifted its stake in Actuate Therapeutics by 0.9% during the third quarter. BIOS Capital Management LP now owns 10,049,996 shares of the company’s stock worth $67,234,000 after purchasing an additional 84,917 shares during the last quarter. Voss Capital LP lifted its stake in Actuate Therapeutics by 45.0% during the fourth quarter. Voss Capital LP now owns 1,300,000 shares of the company’s stock worth $7,956,000 after purchasing an additional 403,722 shares during the last quarter. Vanguard Group Inc. lifted its stake in Actuate Therapeutics by 19.5% during the third quarter. Vanguard Group Inc. now owns 316,010 shares of the company’s stock worth $2,114,000 after purchasing an additional 51,546 shares during the last quarter. Geode Capital Management LLC lifted its stake in Actuate Therapeutics by 42.9% during the fourth quarter. Geode Capital Management LLC now owns 207,744 shares of the company’s stock worth $1,271,000 after purchasing an additional 62,332 shares during the last quarter. Finally, Texas Capital Bank Wealth Management Services Inc purchased a new position in shares of Actuate Therapeutics in the fourth quarter worth about $579,000.

About Actuate Therapeutics

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.